Effects of diltiazem on netilmicin-induced nephrotoxicity in rabbits.
Aminoglycoside nephrotoxicity remains a common clinical problem and is the major cause of acute toxic renal failure in hospitalized patients. In recent studies, calcium channel blockers gave controversial results in the prevention of acute ischemic or toxic renal failure. The aims of the study were (i) to describe a rabbit model of mild renal failure (50% reduction in glomerular filtration rate with a mean value of 1.78 +/- 0.46 ml/kg/min) induced by netilmicin given intramuscularly at 20 mg/kg of body weight every 8 h for 5 days, (ii) to investigate the protective effect of diltiazem given at a therapeutic dose (1 mg/kg given intramuscularly every 8 h for 5 days), and (iii) to investigate the mechanisms of this protection through evaluation of function tests, optic histology, and glomerular morphometry. Animals treated with netilmicin and diltiazem exhibited an unchanged glomerular filtration rate compared with controls (3.39 +/- 0.58 versus 3.68 +/- 0.78 ml/kg/min, respectively). This protective effect was not associated with any change in systemic or renal hemodynamics (i.e., no change in renal plasma flow) or changes in the pharmacokinetics of netilmicin, as assessed by fractional excretion and cortical uptake. Netilmicin-induced tubular toxicity was unchanged by diltiazem. Our results suggest that (i) netilmicin exhibits a toxic effect at both the glomerular and the tubular levels, (ii) diltiazem, a calcium channel blocker, when given at low therapeutic doses, is able to prevent the aminoglycoside-induced renal failure through a potential glomerular mechanism. The precise mechanisms of the protection remain to be elucidated. These results deserve clinical evaluation in high-risk patients.
Lortholary
O
O
Institut National de la Santé et de la Recherche Médicale U. 13, Paris, France.
Blanchet
F
F
Nochy
D
D
Heudes
D
D
Seta
N
N
Amirault
P
P
Carbon
C
C
D000450:Aldosterone / Q000097:blood; D000818:Animals; D001784:Blood Gas Analysis; D004110:Diltiazem / Q000494:pharmacology*; D005740:Gases / Q000652:urine; D007444:Inulin; D007668:Kidney / Q000473:pathology; D007677:Kidney Function Tests; D007678:Kidney Glomerulus / Q000378:metabolism / Q000473:pathology; D007684:Kidney Tubules / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009428:Netilmicin / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics / Q000633:toxicity*; D009994:Osmolar Concentration; D011817:Rabbits; D051437:Renal Insufficiency / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D017595:Renal Plasma Flow / Q000187:drug effects; D010130:p-Aminohippuric Acid / Q000378:metabolism
D005740:Gases; D000450:Aldosterone; D009428:Netilmicin; D007444:Inulin; D004110:Diltiazem; D010130:p-Aminohippuric Acid